AbCellera Biologics Inc. (ABCL) Form 8-K — Jun 5, 2026
AbCellera Biologics Inc. (ABCL) appointed Victor Sandor as a new independent director to its Board of Directors, effective June 1, 2026. Dr. Sandor will serve until the next annual meeting of shareholders and is deemed independent under NASDAQ rules.
Price after filing
1 day: 0.0%7 days: -17.3%30 days: +27.3%
Close on the filing date to close N calendar days later (from $6.37). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.